A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Nave High-Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Study of Gemcitabine and Docetaxel Treatment in Patients with Bladder Cancer (BRIDGE)
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAU9032
U.S. Govt. ID: NCT05538663
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (TURBT) followed by instillations of Bacillus Calmette-Guerin (BCG) immunotherapy into the bladder via a catheter. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer.
This study is closed
Andrew Lenis, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with bladder cancer? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator